Air Liquide Sante (International) Patent applications |
Patent application number | Title | Published |
20150159808 | High Pressure Packaging For A NO/Nitrogen Gaseous Mixture - The invention concerns a method of storing a NO/N2 mixture in a packaging container, in particular a gas bottle, having an internal volume less than or equal to 12 liters, characterized in that a NO/N2 gaseous mixture containing between 400 ppm and 1000 ppm by volume of NO and nitrogen for the remainder is held at a pressure of at least 250 bar in the internal volume of said container. Preferably, the NO/N2 gaseous mixture is held at a pressure of 280 to 450 bar, and preferably between 300 and 420 bar. | 06-11-2015 |
20140144440 | DOSIMETRIC THERAPEUTIC GAS DELIVERY METHOD WITH FEED BACK CONTROL FOR RAPID DOSIMETRY ADJUSTMENT AND OPTIMIZATION - The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitrogen Dioxide exposure. | 05-29-2014 |
20140144439 | DOSIMETRIC THERAPEUTIC GAS DELIVERY SYSTEM FOR RAPID DOSE MONITORING AND CONTROL - The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitric Oxide and Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitric Oxide and Nitrogen Dioxide exposure. | 05-29-2014 |
20140144434 | DOSIMETRIC THERAPEUTIC GAS DELIVERY METHOD FOR NITRIC OXIDE UTILIZATION MONITORING AND CONTROL - The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitrogen Dioxide exposure. | 05-29-2014 |
20140144433 | DOSIMETRIC THERAPEUTIC GAS DELIVERY SYSTEM FOR NITRIC OXIDE UTILIZATION MONITORING AND CONTROL - The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitrogen Dioxide exposure. | 05-29-2014 |
20140120184 | ARGON-BASED INHALABLE GASEOUS MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROINTOXICATIONS - The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms. | 05-01-2014 |
20140024689 | REDUCING FORMALDEHYDE EMISSIONS IN FORMAL-CONTAINING COMPOSITIONS - Method for reducing the formaldehyde emission of a composition containing a formal by adding urea, urea derivatives, amino acids, guanidine or guanidine derivatives. | 01-23-2014 |
20130231397 | SYNERGISTIC PREPARATIONS BASED ON MIXTURES OF GLYCEROL ETHER WITH AROMATIC ALCOHOL FOR CONTROLLING MYCOBACTERIA - A method of preserving a cosmetic product by adding to the cosmetic product a concentrate, which may be in anhydrous form, which includes (a) 1-(2-ethylhexyl) glycerol ether, and (b) one or more aromatic alcohols, (a) and (b) having a weight ratio of (a)/(b) is less than or equal to 0.15. | 09-05-2013 |
20130177654 | XENON-BASED ANESTHETIC GAS COMPOSITION USABLE DURING AN ENDARTERECTOMY INVOLVING THE CLAMPING OF THE CAROTID ARTERY - The invention relates to a xenon-based anesthetic gas composition to be used, via inhalation, to maintain or preserve cerebral perfusion during an endarterectomy involving the clamping of the carotid artery in a mammal under general anesthesia. The xenon is preferably used in combination with at least one injectable anesthetic morphine agent such as remifentanil, sulfentanil, fentanyl, and alfentanil. Advantageously, the xenon is mixed with an oxygen-containing gas and administered to the patient after the patient has been anesthetized, put to sleep, and intubated. The use of xenon makes it possible to achieve a reduction in the pressure gradient during the clamping of the internal carotid artery relative to the usual anesthetic agents, and to achieve stable hemodynamics. | 07-11-2013 |
20130133780 | INSTALLATION FOR FILLING GAS CYLINDERS WITH AN ANGULAR GAS-DISTRIBUTION DEVICE - The invention relates to an installation for filling gas containers ( | 05-30-2013 |
20120312416 | METHOD FOR PACKAGING NO/N2 MIXTURES, WITH PRIOR PURGING AND RINSING STEPS - The method for packaging a gaseous NO/N | 12-13-2012 |
20120232168 | LIQUID CONCENTRATE FOR PRESERVING COSMETICS - A liquid concentrate for preserving cosmetic products which includes a combination of carboxylic component being sodium benzoate and an alcohol component being a mixture of phenoxy ethanol and benzyl alcohol, in a water, where the combination is greater than 45% by weight of the liquid concentrate. | 09-13-2012 |
20110269847 | STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS - Compositions having a combination
| 11-03-2011 |
20110237626 | COMPOSITIONS FOR HYGIENIC HAND DISINFECTION AND DISINFECTANT HANDWASHING - The invention relates to a disinfectant composition which includes a) one or more 1- or 2-(C | 09-29-2011 |
20110218250 | COMPOSITION BASED ON GLYCEROL ETHER/POLYOL MIXTURES - The invention relates to compositions which comprise one or more glycerol ethers together with one or more diol/diols and/or polyol/polyols. As a result, as well as good microbicidal effectiveness, whitening is reduced or avoided, drying-out of the skin is prevented, the moisture content is regulated and the skin is regreased to an adequate extent. | 09-08-2011 |
20110132468 | VALVE SYSTEM FOR A FLUID CHANNEL - A valve system ( | 06-09-2011 |
20110086107 | ARGON-BASED INHALABLE GASEOUS MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROINTOXICATIONS - The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms. | 04-14-2011 |
20110003857 | STABILIZED, ANTIMICROBIALLY EFFECTIVE COMPOSITION WITH A CONTENT OF BISPYRIDINIUM ALKANE - An aqueous-based composition which includes a) at least one bispyridinium alkane (for example octenidine) and b) at least one stabilizer selected from antioxidants, complexing agents, reducing agents, UV filters and photoprotective agents, in particular α-tocopherol, and BHT. The composition can also include c) one or more auxiliaries selected from, for example, nonionic surfactants, ethers, solvents and polymers, in particular fatty alcohol alkoxylates and alkoxylated fatty acid monoglycerides. The presence of the stabilizer reduces or prevents the appearance of decomposition products of bispyridinium alkanes and, in the case of the presence of auxiliaries, of decomposition products of the auxiliaries, such as ethers and peroxides. | 01-06-2011 |
20100331426 | Synergistic preparations based on mixtures of glycerol ether with aromatic alcohol for controlling mycobacteria - Disinfectant which has activity towards mycobacteria and has (a) 1-(2-ethylhexyl} glycerol ether and (b) one or more aromatic alcohols group including aryloxyalkanols, ethers and arylalkanols. | 12-30-2010 |
20100310487 | ACTIVE INGREDIENT COMBINATION AND USE THEREOF - An active ingredient combination which comprises a) glycerol monoalkyl ether, b) bispyridinium alkane, c) polyol and d) antioxidant. The combination is advantageously used for producing a preparation for the treatment of undesired body odour, for example for producing a cosmetic deodorant preparation, an antidandruff hair cleansing composition, a preparation for the treatment of blemished skin and acne or a preparation for the treatment of foot and/or skin fungus. | 12-09-2010 |
20100216677 | METHODS FOR PRESERVING TECHNICAL PRODUCTS SUCH AS FUELS AND LUBRICANTS WITH A MICROBICIDAL COMPOSITION - Methods for preserving technical products such as fuels and lubricants with a microbicidal composition. The composition is made up of at least one formaldehyde donor compound and at least one antioxidant. The antioxidant is either a gallic ester, a phenol derivative, a L-ascorbic acid, including salts and derivatives thereof, a tocopherol or one of its associated derivatives. | 08-26-2010 |
20090123577 | LIQUID CONCENTRATE FOR PRESERVING COSMETICS - The invention relates to a liquid concentrate for preserving cosmetic products which comprises a combination of carboxylic acid salts chosen from the salts of benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydracetic acid, formic acid or 10-undecylenic acid and alcohols chosen from 2-phenoxyethanol, benzyl alcohol, phenethyl alcohol, 1-phenoxypropan-2-ol, 3-(4-chlorophenoxy)-1,2-propanediol, chlorobutanol or 2,4-dichlorobenzyl alcohol in a solvent, where the active ingredient content is greater than 45% by weight. | 05-14-2009 |
20090099188 | MICROBICIDAL COMPOSITION BASED ON FORMALDEHYDE DONOR COMPOUNDS AND ANTIOXIDANTS - A microbicidal composition and its method of use for preserving technical products such as fuels and lubricants. The composition is made up of at least one formaldehyde donor compound and at least one antioxidant. The antioxidant is either a gallic ester, a phenol derivative, a L-ascorbic acid, including salts and derivatives thereof, a tocopherol or one of its associated derivatives. | 04-16-2009 |
20090012135 | ISOTHIAZOLONE-CONTAINING PRESERVATIVE WITH IMPROVED EFFECTIVENESS - The invention relates to a preservative which 5 comprises a) one or more isothiazolones and b) one or more glycerol monoalkyl ethers, to the use of the preservatives for microbicidal finishing of cosmetic and pharmaceutical products, and to corresponding microbicidally finished products. | 01-08-2009 |
20080300283 | Microbicidal preparations based on 1, 2-benzisothiazonlin-3-one with a content of aromatic alcohol - The invention relates to microbicidal preparations which comprise a) at least one of 1,2-benzisothiazolin-3-one and its derivatives, b) at least one of 2-mercaptopyridine N-oxide, its salts and derivatives, c) at least one aromatic alcohol and d) at least one alkalinizing agent, or which are prepared by mixing components a) to d), where the preparations have a pH of at least 11. The preparations are characterized by the fact that they are clear and storage-stable, and they are suitable for use as preservatives. | 12-04-2008 |
20080255015 | COMPOSITION BASED ON GLYCEROL ETHER/POLYOL MIXTURES - The invention relates to compositions which comprise one or more glycerol ethers together with one or more diol/diols and/or polyol/polyols. As a result, as well as good microbicidal effectiveness, whitening is reduced or avoided, drying-out of the skin is prevented, the moisture content is regulated and the skin is regressed to an adequate extent. | 10-16-2008 |
20080254084 | Antimicrobial Preparations Having a Content of Octenidine Dihydrochloride Encapsulated in Liposomes - The invention relates to antimicrobial preparations which comprise octenidine dihydrochloride in liposomes. The invention additionally relates to a process for manufacturing the preparations and to the use of phospholipids for manufacturing antimicrobial preparations which comprise octenidine dihydrochloride. The preparations show a low cytoxicity. | 10-16-2008 |